Arcturus Therapeutics — Third Quarter 2026 Earnings Summary

Arcturus Therapeutics reported a net loss of $7.4 million for the third quarter of 2026, driven by research and development expenses of $17.0 million. The company's cash position decreased to $184.8 million as of September 30, 2026, primarily due to ongoing clinical development activities, though this was partially offset by a $12.0 million termination payment from CSL Seqirus. Pipeline updates include the completion of Phase 2 enrollment for ARCT-032 in cystic fibrosis by year-end 2026 and the introduction of the LUNAR 2.0 delivery platform, which showed a 38-fold potency improvement in non-human primate studies. Additionally, Arcturus plans to initiate Phase 2 dosing for ARCT-2601, its first LUNAR 2.0-formulated candidate for OTC deficiency, in the first quarter of 2027.